This is a Multi-center, Double-masked, Randomized, Vehicle-controlled Study Testing PL9643, an Opthalmic Solution, to Determine if it is Safe and Efficacious for Dry Eye Patients
Latest Information Update: 29 Aug 2024
At a glance
- Drugs PL 9643 (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms MELODY-1
- Sponsors Palatin Technologies
- 28 Aug 2024 Status changed from active, no longer recruiting to completed, According to a Palatin Technologies Media Release.
- 15 May 2024 According to a Palatin Technologies Media Release, Type C meeting with the FDA on key elements of the pivotal Phase 3 clinical program is expected in the third quarter of calendar year 2024. NDA submission targeted for second half of calendar year 2025
- 08 Apr 2024 According to a Palatin Technologies Media Release, topline results of this study were presented at the American Society of Cataract and Refractive Surgery (ASCRS).